Drug development in hepatocellular carcinoma had essentially stalled since 2008 when sorafenib was established as the modest standard of care. Now, a positive result in a phase III study evaluating regorafenib challenges us to weigh its clinical significance as well as its real-world benefits and potential harms.
This is a preview of subscription content, log in via an institution to check access.
References
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Sun, H. C. et al. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J. Cancer Res. Clin. Oncol. 125, 419–426 (1999).
Llovet, J. M., Villanueva, A., Lachenmayer, A. & Finn, R. S. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat. Rev. Clin. Oncol. 12, 408–424 (2015).
Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2016).
Wilhelm, S. M. et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129, 245–255 (2011).
Scher, K. S. & Hurria, A. Under-representation of older adults in cancer registration trials: known problem, little progress. J. Clin. Oncol. 30, 2036–2038 (2012).
Mailankody, S. & Prasad, V. Overall survival in cancer drug trials as a new surrogate end point for overall survival in the real world. JAMA Oncol. http:dx.doi.org/10.1001/jamaoncol.2016.5296 (2016).
Abou-Alfa, G. K. et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest. Cancer Res. 4, 40–44 (2011).
Sanoff, H. K., Chang Y., Lund, J. L., O'Neil, B. H. & Dusetzina, S. B. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist 21, 1113–1120 (2016).
Author information
Authors and Affiliations
Contributions
Both authors researched data for the article and contributed to the discussion of content for the article. A.G.D. wrote the article and T.F.G. reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Duffy, A., Greten, T. Regorafenib as second-line therapy in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 14, 141–142 (2017). https://doi.org/10.1038/nrgastro.2017.7
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.7
- Springer Nature Limited
This article is cited by
-
Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression
Clinical and Translational Oncology (2020)
-
Regorafenib regressed a doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model
Cancer Chemotherapy and Pharmacology (2019)
-
The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma
Cancer Immunology, Immunotherapy (2019)
-
Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research
Nature Reviews Gastroenterology & Hepatology (2018)
-
Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer
Journal for ImmunoTherapy of Cancer (2017)